

#9/5/2001
1623-02

OIIPE

RECEIVED

JAN 18 2002

TECH CENTER 1600/2900

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,419

DATE: 12/14/2001

TIME: 15:37:37

Input Set : N:\Crf3\RULE60\09724319.txt

Output Set: N:\CRF3\12142001\I724419.raw

3 <110> APPLICANT: Schenk, Dale B.
 4 Neuralab Limited
 6 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
 8 <130> FILE REFERENCE: 15270J-004740US
 C--> 10 <140> CURRENT APPLICATION NUMBER: US/09/724,419
 11 <141> CURRENT FILING DATE: 2000-11-27
 13 <150> PRIOR APPLICATION NUMBER: 09/322,289
 14 <151> PRIOR FILING DATE: 1999-05-28
 16 <160> NUMBER OF SEQ ID NOS: 5
 18 <170> SOFTWARE: PatentIn Ver. 2.1
 20 <210> SEQ ID NO: 1
 21 <211> LENGTH: 42
 22 <212> TYPE: PRT
 23 <213> ORGANISM: Homo sapiens
 25 <220> FEATURE:
 26 <223> OTHER INFORMATION: human Abeta42 beta-amyloid peptide
 28 <400> SEQUENCE: 1
 29 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 30 1 5 10 15
 32 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
 33 20 25 30
 35 Gly Leu Met Val Gly Gly Val Val Ile Ala
 36 35 40
 39 <210> SEQ ID NO: 2
 40 <211> LENGTH: 13
 41 <212> TYPE: PRT
 42 <213> ORGANISM: Artificial Sequence
 44 <220> FEATURE:
 45 <223> OTHER INFORMATION: Description of Artificial Sequence: Abetal-12
 46 peptide with carboxyl terminal Cys residue
 47 inserted
 49 <400> SEQUENCE: 2
 50 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys
 51 1 5 10
 54 <210> SEQ ID NO: 3
 55 <211> LENGTH: 6
 56 <212> TYPE: PRT
 57 <213> ORGANISM: Artificial Sequence
 59 <220> FEATURE:
 60 <223> OTHER INFORMATION: Description of Artificial Sequence: Abetal-5
 61 peptide with carboxyl terminal Cys residue
 62 inserted
 64 <400> SEQUENCE: 3
 65 Asp Ala Glu Phe Arg Cys
 66 1 5
 69 <210> SEQ ID NO: 4
 70 <211> LENGTH: 12

ENTERED

RAW SEQUENCE LISTING

DATE: 12/14/2001

PATENT APPLICATION: US/09/724,419

TIME: 15:37:37

Input Set : N:\Crf3\RULE60\09724319.txt

Output Set: N:\CRF3\12142001\I724419.raw

```

71 <212> TYPE: PRT
72 <213> ORGANISM: Artificial Sequence
74 <220> FEATURE:
75 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta33-42
76     peptide with carboxyl terminal Cys residue
77     inserted
79 <220> FEATURE:
80 <221> NAME/KEY: MOD_RES
81 <222> LOCATION: (2)
82 <223> OTHER INFORMATION: Xaa = amino heptanoic acid
84 <400> SEQUENCE: 4
W--> 85 Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
86     1             5             10
89 <210> SEQ ID NO: 5
90 <211> LENGTH: 19
91 <212> TYPE: PRT
92 <213> ORGANISM: Artificial Sequence
94 <220> FEATURE:
95 <223> OTHER INFORMATION: Description of Artificial Sequence:Abeta13-28
96     peptide with carboxyl terminal Cys residue
97     inserted and two added Gly residues
99 <220> FEATURE:
100 <221> NAME/KEY: MOD_RES
101 <222> LOCATION: (1)
102 <223> OTHER INFORMATION: Xaa = acetyl histidine
104 <400> SEQUENCE: 5
W--> 105 Xaa His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
106     1             5             10             15
108 Gly Gly Cys

```

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/724,419

DATE: 12/14/2001

TIME: 15:37:39

Input Set : N:\Crf3\RULE60\09724319.txt

Output Set: N:\CRF3\12142001\I724419.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application Number
L:85 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:105 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5